Pharma News - Drug Trials News & Articles

101 NPS pharmaceuticals recognized by national organization for rare disorders for gattex as an innovative treatment for patients with short bowel syndrome Full Text NPS Pharmaceuticals, May 23, 2013

102 Effect of excipients on dissolution enhancement of aceclofenac solid dispersions studied using response surface methodology: a technical note Full Text Archives of Pharmacal Research, May 23, 2013    Clinical Article

103 German federal joint committee (g-ba) issues final assessment report for pixuvri (pixantrone) Full Text Cell Therapeutics, May 22, 2013

104 Phase III results: tiotropium respimat effective in symptomatic asthma patients despite at least ics/laba independent of their age, allergic status, smoking status and bronchodilator response Full Text Boehringer Ingelheim, May 22, 2013

105 Asco 2013: Boehringer Ingelheim to present highly anticipated new phase iii results for front-runner compounds afatinib and nintedanib in first- and second-line nsclc treatment Full Text Boehringer Ingelheim, May 22, 2013

106 Results from phase III studies of naloxegol for treatment of opioid-induced constipation presented at digestive disease week 2013 Full Text AstraZeneca, May 22, 2013

107 Asco 2013: new phase III data reveal targeted treatment with afatinib or with nintedanib improves progression-free survival in patients with advanced NSCLC Full Text Boehringer Ingelheim, May 22, 2013

108 New data reinforces strength of novartis once-daily copd portfolio in improving lung function, shortness of breath and reducing rate of exacerbations Full Text Novartis, May 22, 2013

109 Sanofi and regeneron announce publication of positive phase 2a results of dupilumab in asthma in the new England journal of medicine Full Text Sanofi, May 22, 2013

110 Boston scientific long term data demonstrate bronchial thermoplasty treatment benefits persist out to five years in patients with severe asthma Full Text Boston Scientific, May 22, 2013

111 A randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis Hepatology, May 22, 2013    Clinical Article

112 Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility Full Text Pfizer, May 21, 2013

113 Site of Care May Impact Breast Cancer Management and Economic Outcomes Full Text First Report Managed Care, May 20, 2013

114 Hepatitis C Treatment Options Likely to Expand Full Text First Report Managed Care, May 20, 2013

115 Takeda and Lundbeck Present Results from Pivotal Phase 3 Clinical Trials with Vortioxetine, an Investigational Compound for Major Depressive Disorder Full Text Takeda Pharmaceuticals U.S.A., May 20, 2013

116 Europe Faces Persistent Gaps in International GCP Inspections Full Text Applied Clinical Trials, May 20, 2013

117 Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis Full Text Sanofi, May 20, 2013

118 Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus Full Text Sarepta Therapeutics, May 20, 2013

119 Vortioxetine clinical phase III data show significant improvement in symptoms of major depression Full Text Lundbeck, May 20, 2013

120 First Patient Enrolled In Boston Scientific Randomized Study Comparing WallFlex Biliary RX Stent To Absence Of Biliary Drainage In Patients With Pancreatic Or Periampullary Cancers Full Text Boston Scientific, May 17, 2013

1 Hepatitis C Treatment Options Likely to Expand First Report Managed Care, May 20, 2013    Free full text

2 Transarterial Chemoembolization Using DEBIRI for Treatment of Hepatic Metastases from Colorectal Cancer Anticancer Research, May 8, 2013

3 Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective Clinical Pharmacology & Therapeutics, May 6, 2013

4 Legislation to protect subjects in clinical trials introduced BioPharm International, May 29, 2013    Free full text

5 Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility Pfizer, May 21, 2013    Free full text

6 New Four-Year Data From Boston Scientific Demonstrated WATCHMAN Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial Boston Scientific, May 10, 2013    Free full text

7 Semen-Derived Enhancer of Viral Infection (SEVI) Binds Bacteria, Enhances Bacterial Phagocytosis by Macrophages, and Can Protect against Vaginal Infection by a Sexually Transmitted Bacterial Pathogen Antimicrobial Agents and Chemotherapy, May 15, 2013    Review Article

8 Sanofi and regeneron announce publication of positive phase 2a results of dupilumab in asthma in the new England journal of medicine Sanofi, May 22, 2013    Free full text

9 FDA Approves Mercks LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol Merck, May 8, 2013    Free full text

10 Teva Presented New Data from Phase III Clinical Trial of Milprosa (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society Teva Pharmaceutical Industries, April 22, 2013    Free full text

11 Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus BMC Pharmacology & Toxicology, May 9, 2013    Free full text

12 Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland The European Journal of Health Economics, May 2, 2013

13 German federal joint committee (g-ba) issues final assessment report for pixuvri (pixantrone) Cell Therapeutics, May 22, 2013    Free full text

14 Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development Clinical Pharmacology & Therapeutics, May 14, 2013    Review Article

15 A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer Investigational New Drugs, May 7, 2013

16 Merck Provides Update on IMPROVE-IT Trial Merck, March 13, 2013    Free full text

17 Clinical trial discussion, referral, and recruitment: physician, patient, and system factors Cancer Causes and Control, May 1, 2013    Review Article

18 High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naive Patients with Genotype 1 Chronic Hepatitis C Infection Bristol Myers-Squibb, May 6, 2013    Free full text

19 Roche to present important new data reflecting broad cancer pipeline at ASCO Roche, May 16, 2013    Free full text

20 Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation Bristol Myers-Squibb, May 7, 2013    Free full text